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Summary
Background.— In France, the reported decrease in cardiovascular death is due partly to
improved cardiovascular prevention. The management of dyslipidaemias remains a priority of
preventive cardiology.
Aim.— To assess trends in lipids, lipoproteins and dyslipidaemias between 1996 and 2007 in
France.
Methods.— Representative surveys of the general population were carried out in Lille, Stras-
bourg and Toulouse during two periods, 1996 to 1997 and 2006 to 2007. Men and women aged
35 to 64 years were included. Investigators recorded cardiovascular risk factors, and a blood
sample was drawn to measure glycaemia and to provide a complete lipid proﬁle. The data
were corrected according to the respective original populations to study 10-year trends in the
parameters measured.
∗ Corresponding author. Service de cardiologie B, CHU Rangueil, TSA 50032, 31059 Toulouse cedex 9, France.
E-mail address: ferrieres.j@chu-toulouse.fr (J. Ferrières).
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lipidémies en France. La baisse signiﬁcative du LDL-cholestérol enregistrée chez l’ensemble des
sujets et plus particulièrement chez les sujets traités par un hypolipidémiant doit encourager
les médecins à une prise en charge de la population franc¸aise adulte.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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DL high-density lipoprotein
DL low-density lipoprotein
E standard error
ackground
ardiovascular diseases are chronic conditions whose man-
gement and prognosis have evolved signiﬁcantly in recent
ears. Primary and secondary prevention practices have
mproved, with better screening of risk factors in patients
ith minor coronary atherosclerosis and with treatment of
atients with chronic disease. Hence, death due to cardio-
ascular diseases in France has decreased by 52% between
980 and 2004 [1].
While improved management of acute forms of cardio-
ascular diseases will continue, only systematic treatment
f risk factors will prevent new cases of coronary artery dis-
ase from occurring. Management of tobacco consumption,
n
F
t
1
pypercholesterolemia, high blood pressure and diabetes
orm the fundamental basis for cardiovascular prevention.
ontrol of high blood pressure has been a concern for a long
ime, but the aggressive treatment of hypercholesterolemia
s a relatively recent priority in France [2]. A great number of
ndustrialized countries have set targets for blood pressure,
holesterolaemia values and other risk factors [3]. This is
lso the case in France, where precise objectives concerning
he control of the various risk factors have been stipulated
n Public Health law [4].
To assess trends in risk factors in France, representa-
ive surveys of the general population are needed. Since
985, the French Multinational MONItoring of trends and
eterminants in CArdiovascular disease (MONICA) Project
as carried out a continuous survey of coronary artery
isease in France and assessed classical risk factors for coro-294 J. Ferrières et al.
Results.— From 1996 to 2007, a signiﬁcant 5.7% decrease in low-density lipoprotein (LDL)-
cholesterol levels was observed in adults aged 35 to 64 years (p < 0.001). This decrease was
greater in those aged 55 to 64 years (10.8% in men, 8.4% in women). A signiﬁcant 7.8% increase
in triglycerides was observed (p < 0.001) over the same period. Variation in LDL-cholesterol was
more striking in subjects treated with a lipid-lowering drug, with a 17.6% reduction (p < 0.001).
A decrease in most of dyslipidaemias was also observed over this 10-year interval.
Conclusion.— This study shows a favourable downward trend in LDL-cholesterol concentration
and dyslipidaemias in France. The signiﬁcant decrease in LDL-cholesterol observed among all
the subjects and more particularly among subjects treated with lipid-lowering drugs should
provide an incentive for physicians to support the management of all French adults.
© 2009 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— L’amélioration de la prévention cardiovasculaire a contribué à la baisse de la mor-
talité cardiovasculaire en France. La prise en charge des dyslipidémies fait partie des priorités
de la cardiologie préventive. Le but de ce travail a été d’évaluer l’évolution des lipides, des
lipoprotéines et des dyslipidémies de 1996 à 2007 en France.
Méthodes.— Deux enquêtes représentatives de la population générale ont été réalisées dans les
régions de Lille, Strasbourg et Toulouse en 1996 à 1997 et en 2006 à 2007. Ces deux enquêtes ont
inclus des hommes et des femmes de 35 à 64 ans. Les enquêteurs ont recueilli l’ensemble des
facteurs de risque cardiovasculaire et une prise de sang a été réalisée pour évaluer la glycémie
et le bilan lipidique complet. Les données ont été redressées sur les populations d’origine de
fac¸on à étudier l’évolution à dix ans des paramètres mesurés.
Résultats.— De 1996 à 2007, le LDL-cholestérol chez les sujets adultes de 35 à 64 ans a baissé
signiﬁcativement de 5,7 % (p < 0,001). Cette baisse a été plus marquée dans la tranche d’âge
de 55 à 64 ans (10,8 % chez les hommes et 8,4 % chez les femmes). Durant la même période,
on a enregistré une augmentation signiﬁcative de 7,8 % des triglycérides (p < 0,001). La baisse
du LDL-cholestérol a été beaucoup plus marquée chez les sujets traités par un hypolipidémiant
avec une baisse de 17,6 % (p < 0,001). La plupart des dyslipidémies a diminué signiﬁcativement
à dix ans d’intervalle.
Conclusion.— Cette étude montre une évolution favorable du LDL-cholestérol et des dys-ary atherosclerosis through representative surveys of the
rench population [5]. The aim of this work was to assess
rends in lipids, lipoproteins and dyslipidaemias between
996 and 2007 from representative surveys of the French
opulation.
renc
U
i
c
H
a
i
g
B
d
l
S
H
t
a
H
1
(
w
p
(
(
6
f
u
s
m
i
a
a
a
T
b
W
a
d
a
v
n
9
R
A
(
l
a
A
r
m
a
c
w
fTrends in plasma lipids, lipoproteins and dyslipidaemias in F
Methods
Population sample
Participants were recruited in the framework of the World
Health Organization MONICA population survey [6—9], con-
ducted between 1996 and 1997, and in the MONA LISA
survey, carried out between 2006 and 2007 [10], in three
different parts of France: the Lille Urban Community in
Northern France, the Bas-Rhin county in Eastern France and
the Haute-Garonne county in Southern France. The protocol
was approved by the appropriate independent ethics com-
mittees. Subjects (aged 35—64 years in the ﬁrst survey and
35—74 years in the second) were selected randomly from
electoral rolls after stratiﬁcation by town size, sex and age,
in order to obtain 200 participants for each sex and each
10-year age group, with the same sampling frame in the
two surveys. Participation rates were 63% for men and 60%
for women in the ﬁrst survey, and 50% for men and 51%
for women in the second survey. A total of 4195men and
4106women completed the recruitment procedure.
Data collection
After providing written informed consent, participants ﬁlled
out a standard questionnaire and physical measurements
were taken by a specially trained nurse. An identical
methodology was used in the three centres and in the two
surveys. Subjects provided information on demographic vari-
ables, socioeconomic status and medical history including
medication use, smoking and alcohol consumption using a
questionnaire, which was completed with the help of med-
ical staff. A physical examination was performed in the
morning and a fasting blood sample was drawn. The level
of leisure-time physical activity was categorized as follows:
none, light (light physical activity almost every week), or
intense (at least 20minutes of intense physical activity more
than once a week). In terms of smoking exposure, sub-
jects were categorized as never-smokers, former smokers
and current smokers (i.e., subjects reporting at least one
cigarette per day). Total alcohol intake was expressed as
the sum of milliliter alcohol per week from wine, beer,
cider and spirits. Anthropometric measurements included
height, body weight (rounded to the nearest even decimal)
and waist circumference (at a mid level between the lower
rib margin and the iliac crest, to the nearest 0.5 cm), and
were performed in subjects in light clothing without shoes.
Body mass index was calculated according to the Quetelet
equation.
Blood pressure measurements were performed with a
standard sphygmomanometer (OMRON 705IT) using cuff size
adapted to the subject’s arm circumference. Heart rate and
blood pressure were measured twice with the patient in
the sitting position. The average of the two blood pressure
measurements was used for statistical analysis.
Biological measurementsA 20-ml blood sample was drawn into a disodium EDTA tube
(after the subjects had fasted for at least 10 hours), stored at
room temperature and centrifuged within 4 hours. All mea-
surements were performed in a central laboratory (Toulouse
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niversity Hospital in 1996-1997 and Pasteur Institute of Lille
n 2006—2007, France). Cholesterol and triglyceride con-
entrations were measured using enzyme assays (Olympus).
igh-density lipoprotein (HDL) cholesterol was measured
fter sodium phosphotungstate/magnesium chloride precip-
tation (Olympus). Glucose was measured using the standard
lucose hexokinase method (DuPont Dimension, Brussels,
elgium). Low-density lipoprotein (LDL) cholesterol was
etermined by the Friedewald equation only if triglycerides
evels were lower than 4.56mmol/l (4 g/l).
tatistical analysis
igh LDL-cholesterol was deﬁned as LDL-cholesterol greater
han 4.1mmol/l (1.60 g/l). High triglycerides were deﬁned
s triglycerides greater or equal to 2.3mmol/l (2 g/l). Low
DL-cholesterol was deﬁned as HDL-cholesterol less than
.05mmol/l (0.40 g/l) in men or less than 1.30mmol/l
0.50 g/l) in women. Prevalence of hypercholesterolaemia
as deﬁned as patients on lipid-lowering treatment or
atients with LDL-cholesterol greater than 4.1mmol/l
1.60 g/l) or, if triglycerides greater than 4.56mmol/l
4 g/l), patients with total cholesterol greater than
.45mmol/l (2.5 g/l).
Percentages or means and standard errors were given
or each table. Means and percentages of the ﬁnite pop-
lation were estimated from survey data considering the
tratiﬁcation sample design by age, sex and region. Esti-
ates were obtained by computing weighted averages of the
ndividual stratum-speciﬁc estimates and aggregating them
cross strata [11]. Standard errors of the means or percent-
ges were estimated taking into account the sample weights
nd sample design by using Taylor series linearization [12].
he variation in the levels of each plasma lipid parameter
etween the two population surveys was analysed using the
ald test. For serum triglycerides, analyses were performed
fter logarithmic transformation because of a highly skewed
istribution; variation of population means between the ﬁrst
nd the second survey was calculated using geometric mean
alues. A p value < 0.05 was considered to be statistically sig-
iﬁcant. Data analyses were performed with Stata release
.2 [13].
esults
total of 3508 subjects were included in the ﬁrst survey
1996—1997) and 4793 in the second (2006—2007). In the
atter, subjects in the age range 65—74 years (n = 1196) were
lso included but were not taken into account in this paper.
ll the data obtained from the population samples were cor-
ected according to the respective original populations. The
ain risk factors and their trends over the 10-year interval
re presented in Table 1. A signiﬁcant decrease in tobacco
onsumption and in systolic and diastolic blood pressures
as observed whereas body mass index and waist circum-
erence remained stable. The use of lipid-lowering drugs
ncreased signiﬁcantly from 10.4 to 12.5% in the general
opulation (p = 0.004).
Trends in concentrations of the various lipoproteins
ver the 10-year interval are presented in Table 2. These
ata show a signiﬁcant 5.7% decrease in LDL-cholesterol
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Table 1 Baseline demographics, risk factors and medical history in French adults (aged 35—64 years) in 1996—1997 and
in 2006—2007.
Characteristics 1996—1997 (n = 3508) 2006—2007 (n = 3597) p
Body mass index (kg/m2)a 26.2± 0.08 26.1± 0.08 0.48
Waist circumference (cm)a 89.6± 0.22 89.3± 0.21 0.32
Systolic blood pressure (mmHg)a 131.3± 0.31 129.5± 0.28 0.001
Diastolic blood pressure (mmHg)a 82.1± 0.20 80.6± 0.17 0.001
Current smokerb 22.1 (20.6—23.5) 18.9 (17.6—20.2) 0.002
Current hypoglycaemic drugb 3.5 (3.0—4.1) 3.4 (2.9—4.0) 0.78
Hypercholesterolaemiab,c 41.7 (40.1—43.3) 36.9 (35.3—38.4) 0.001
Current lipid-lowering drugb 10.4 (9.4—11.3) 12.5 (11.5—13.5) 0.004
Subjects without dyslipidaemiab,d 45.0 (43.1—46.5) 51.5 (49.7—52.9) 0.001
Medical history
Coronary artery diseaseb 2.53 (2.05—3.01) 2.08 (1.63—2.52) 0.18
Peripheral artery diseaseb 0.94 (0.64—1.23) 0.69 (0.44—0.94) 0.22
Strokeb 0.64 (0.40—0.89) 0.62 (0.38—0.87) 0.89
Chronic kidney diseaseb 0.08 (0.01—0.16) 0.12 (0.01—0.23) 0.51
Cancerb 1.46 (1.09—1.84) 3.59 (3.00—4.17) 0.001
a Mean± standard error.
b Percent (95% conﬁdence interval).
c LDL-cholesterol > 4.1mmol/l (1.60 g/l) or (triglycerides > 4.56mmol/l (4 g/l) and total cholesterol > 6.45mmol/l (2.5 g/l) or treatment.
d Subjects without lipid-lowering drug and with LDL-cholesterol < 4.1mmol/l (1.60 g/l) and triglycerides < 2.3mmol/l (2 g/l) and HDL-
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[cholesterol > 1.05mmol/l (0.40 g/l) in men or HDL-cholesterol > 1.
p < 0.001) between 1996 and 2007. This decrease was more
arked in patients aged 55—64 years (10.8% in men and
.4% in women). A more moderate 1.9% decrease was
bserved for HDL-cholesterol (p < 0.003). Moreover, a signif-
cant 7.8% increase in the geometric mean of triglycerides
as observed (p < 0.001).
When the analysis of lipid trends was performed taking
nto account subjects treated or not treated with lipid-
owering drugs, the magnitude of variation was entirely
ifferent (Table 3). In untreated subjects, the decrease
n LDL-cholesterol was 4.1% (p < 0.001) whereas it reached
7.6% (p < 0.001) in treated subjects. Moreover, a signiﬁ-
ant variation was observed in use of lipid-lowering drugs
n dyslipidaemic subjects. During the period 1996—1997,
3.7% of the dyslipidaemic subjects were treated with
tatins whereas this rate reached 71.8% during the period
006—2007. Conversely, treatment with ﬁbrates decreased
rom 54.1% during the period 1996—1997 to 16.8% dur-
ng the period 2006—2007. In 2006—2007, atorvastatin was
he most commonly prescribed statin (35.8% of all statins)
hereas the most common ﬁbrate was fenoﬁbrate (87.2%
f all ﬁbrates). In the two representative surveys, 12.2%
1996—1997) to 11.4% (2006—2007) of subjects received
ipid-lowering drugs other than statins and ﬁbrates.
The prevalence of the different dyslipidaemias over
he 10-year interval is presented in Fig. 1. We observed
signiﬁcant decrease in the prevalence of pure hyper-
holesterolaemia, of isolated low HDL-cholesterol and of
he combination of low HDL-cholesterol with high LDL-
holesterol. Conversely, we observed a signiﬁcant increase
n the combination of hypertriglyceridaemia with high LDL-
holesterol over the 10-year interval. When we excluded
ubjects treated with lipid-lowering drugs, the same trends
ere shown in the prevalence of the different dyslip-
c
s
i
b
omol/l (0.50 g/l) in women.
daemias over the 10-year interval (Fig. 2), except for
he combination of hypertriglyceridaemia with high LDL-
holesterol, which was not signiﬁcant.
iscussion
n this study, we observed a favourable 6% downward trend
n LDL-cholesterol concentrations in France over a 10-
ear interval. The decrease in LDL-cholesterol was more
ronounced in subjects treated with lipid-lowering drugs.
oreover, French physicians’ practice showed changing pat-
erns, since statins was the most commonly lipid-lowering
rugs used in the most recent survey. Lastly, the preva-
ence of the different dyslipidaemias decreased signiﬁcantly
etween 1996 and 2007.
Agreement between physicians and policy makers con-
erning the management of LDL-cholesterol is relatively
ecent. The beneﬁcial impact of statins on total mortal-
ty in secondary [14] and primary [15,16] prevention had
o be demonstrated before radical changes in patients’
anagement could be achieved. As soon as the efﬁcacy
f lipid-lowering drugs on cardiovascular prognosis and life
xpectancy had been demonstrated, it induced massive
dherence from both prescribers and patients. Observations
f lipid trends are relatively scarce because representative
tudies of the general population are needed to obtain a reli-
ble picture of these changes. In the USA, two major studies
17,18] showed a favourable trend in total cholesterol con-
entrations during recent years. In European population
tudies, it seems that the trend in LDL-cholesterol decreased
n a similar way [19,20]. This favourable trend seems to
e conﬁrmed despite the unfavourable trend in obesity
bserved in some countries [21].
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Table 2 Trends in lipids and lipoproteins in French adults (35—64 years) between 1996—1997 and 2006—2007.
1996—1997 (n = 3508) 2006—2007 (n = 3597) %b p
Mean± SEa (mmol/l)(g/l)
Total cholesterol
Total population (35—64 years) 5.88± 0.02 5.68± 0.02 −3.5 0.001
(2.28± 0.007) (2.20± 0.007)
Men
35—64 years 5.93± 0.03 5.73± 0.03 −3.5 0.001
(2.30± 0.01) (2.22± 0.01)
35—44 years 5.83± 0.05 5.68± 0.05 −2.5 0.02
(2.26± 0.02) (2.2± 0.02)
45—54 years 6.01± 0.05 5.83± 0.05 −2.9 0.004
(2.33± 0.02) (2.26± 0.02)
55—64 years 6.04± 0.05 5.62± 0.05 −6.7 0.001
(2.34± 0.02) (2.18± 0.02)
Women
35—64 years 5.83± 0.03 5.65± 0.02 −3.5 0.001
(2.26± 0.01) (2.19± 0.009)
35—44 years 5.44± 0.05 5.31± 0.05 −2.1 0.04
(2.11± 0.02) (2.06± 0.02)
45—54 years 5.96± 0.05 5.70± 0.05 −4.1 0.001
(2.31± 0.02) (2.21± 0.02)
55—64 years 6.35± 0.05 6.04± 0.05 −5.2 0.001
(2.46± 0.02) (2.34± 0.02)
LDL-cholesterol
Total population (35—64 years) 3.84± 0.02 3.61± 0.02 −5.7 0.001
(1.49± 0.007) (1.40± 0.006)
Men
35—64 years 3.95± 0.03 3.72± 0.02 −6.3 0.001
(1.53± 0.01) (1.44± 0.009)
35-44 years 3.90± 0.05 3.72± 0.05 −4.3 0.005
(1.51± 0.02) (1.44± 0.02)
45—54 years 4.02± 0.05 3.79± 0.05 −5.8 0.001
(1.56± 0.02) (1.47± 0.02)
55—64 years 4.00± 0.05 3.59± 0.05 −10.8 0.001
(1.55± 0.02) (1.39± 0.02)
Women
35—64 years 3.72± 0.03 3.51± 0.02 −5.1 0.001
(1.44± 0.01) (1.36± 0.008)
35—44 years 3.38± 0.05 3.28± 0.05 −3.0 0.05
(1.31± 0.02) (1.27± 0.02)
45—54 years 3.77± 0.05 3.56± 0.05 −5.3 0.001
(1.46± 0.02) (1.38± 0.02)
55—64 years 4.15± 0.05 3.79± 0.05 −8.4 0.001
(1.61± 0.02) (1.47± 0.02)
HDL-cholesterol
Total population (35—64 years) 1.50± 0.01 1.47± 0.01 −1.9 0.003
(0.58± 0.003) (0.57± 0.002)
Men
35—64 years 1.32± 0.01 1.32± 0.01 +0.6 0.94
(0.51± 0.003) (0.51± 0.003)
35—44 years 1.32± 0.02 1.32± 0.02 −0.8 0.61
(0.51± 0.006) (0.51± 0.006)
45—54 years 1.32± 0.02 1.32± 0.02 −0.6 0.68
(0.51± 0.006) (0.51± 0.006)
55—64 years 1.34± 0.02
(0.52± 0.006)
1.34± 0.02 −0.4 0.78
(0.52± 0.006)
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Table 2 (Continued )
1996—1997 (n = 3508) 2006—2007 (n = 3597) %b p
Mean± SEa (mmol/l)(g/l)
Women
35—64 years 1.65± 0.01 1.60± 0.01 −2.2 0.001
(0.64± 0.004) (0.62± 0.003)
35—44 years 1.63± 0.02 1.57± 0.02 −1.8 0.18
(0.63± 0.006) (0.61± 0.006)
45—54 years 1.70± 0.02 1.60± 0.02 −5.7 0.001
(0.66± 0.006) (0.62± 0.006)
55—64 years 1.68± 0.02 1.63± 0.02 −2.9 0.06
(0.65± 0.006) (0.63± 0.006)
Triglycerides
Total population (35—64 years) 1.31± 0.02 1.38± 0.02 +7.8c 0.001
(1.15± 0.02) (1.21± 0.02)
Men
35—64 years 1.53± 0.03 1.61± 0.03 +7.2 0.001
(1.34± 0.03) (1.41± 0.03)
35—44 years 1.49± 0.05 1.47± 0.05 −1.3 0.39
(1.31± 0.04) (1.29± 0.04)
45—54 years 1.60± 0.05 1.73± 0.05 +10.7 0.003
(1.40± 0.04) (1.52± 0.04)
55—64 years 1.53± 0.05 1.62± 0.05 +8.9 0.009
(1.34± 0.04) (1.42± 0.04)
Women
35—64 years 1.08± 0.02 1.15± 0.01 +8.7 0.001
(0.95± 0.02) (1.01± 0.01)
35—44 years 0.96± 0.05 0.99± 0.05 +4.0 0.09
(0.84± 0.04) (0.87± 0.04)
45—54 years 1.19± 0.05 1.20± 0.05 +9.4 0.003
(1.04± 0.04) (1.05± 0.04)
55—64 years 1.16± 0.05 1.32± 0.05 +13.1 0.001
(1.02± 0.04) (1.16± 0.04)
a SE: standard error.
b % of variation between 1996 and 2007.
c Trend for the geometric mean.
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cOur work presents some speciﬁcity due to French medical
ractice. In 1996—1997, ﬁbrates were the most commonly
rescribed lipid-lowering drugs, whereas in 2006—2007,
tatin prescription has become the rule and ﬁbrate use
eclined to 16.8%. During the same period, we observed
very moderate decrease in HDL-cholesterol (0.57 vs
.58 g/l) and a signiﬁcant increase in triglycerides of about
% (1.21 vs 1.15 g/l). Therefore, we registered mainly an
ncrease in triglycerides that was not explained by body
ass index, which remained stable between the two sur-
eys. Despite this a priori unfavourable trend regarding
he two parameters, the prevalence of most dyslipidaemias
ecreased signiﬁcantly between the two periods. Dyslip-
daemias decreased in the whole sample, and also after
xcluding patients on lipid-lowering drugs, reinforcing a true
mprovement in this risk factor in the second survey. The
ombination of high triglycerides with high LDL-cholesterol
as the only dyslipidaemia to show a signiﬁcant increase
rom 1.8 to 3.1% between the two periods.
u
d
d
g
iIn subjects treated with lipid-lowering drugs, we
bserved a 17.6% decrease in LDL-cholesterol and a 16.6%
ncrease in triglycerides. This change may have been
nduced by changes in prescription of lipid-lowering drugs,
ince statins lead to a signiﬁcant decrease in LDL-cholesterol
ut poorer control of triglycerides compared with ﬁbrates.
n fact, the trend in triglycerides in subjects not treated
ith lipid-lowering drugs was less signiﬁcant (6.3% increase
n untreated subjects vs 16.6% in treated subjects). Further-
ore, the trend in the combination of hypertriglyceridaemia
ith high LDL-cholesterol was not signiﬁcant after having
xcluded subjects on lipid-lowering drugs. Thus, we inter-
ret the variation in HDL-cholesterol and triglycerides as a
onsequence of the shift in lipid-lowering drugs at a pop-
lation level. Finally, the prevalence of subjects without
yslipidaemia (globally and in samples not on lipid-lowering
rugs) increased signiﬁcantly between the two surveys, sug-
esting a real impact of primary prevention on lipid levels
n France.
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Table 3 Lipids and lipoproteins in treated and non-treated French adults (35—64 years) between 1996—1997 and
2006—2007.
1996—1997 (n = 3508) 2006—2007 (n = 3597) %b p
Mean± SEa (mmol/l) (g/l)
Adults treated with lipid-lowering drugs
Total cholesterol 6.19± 0.05 5.47± 0.05 −11.6 0.001
(2.4± 0.02) (2.12± 0.02)
LDL-cholesterol 4.08± 0.05 3.35± 0.05 −17.6 0.001
(1.58± 0.02) (1.3± 0.02)
HDL-cholesterol 1.44± 0.02 1.37± 0.02 −5.2 0.006
(0.56± 0.008) (0.53± 0.006)
Triglycerides 1.49± 0.05 1.71± 0.05 +16.6c 0.001
(1.31± 0.04) (1.5± 0.04)
Adults not treated with lipid-lowering drugs
Total-cholesterol 5.86± 0.02 5.70± 0.02 −2.4 0.001
(2.27± 0.007) (2.21± 0.007)
LDL-cholesterol 3.82± 0.02 3.64± 0.02 −4.1 0.001
(1.48± 0.007) (1.41± 0.006)
HDL-cholesterol 1.50± 0.01 1.47± 0.01 −1.3 0.10
(0.58± 0.003) (0.57± 0.002)
Triglycerides 1.29± 0.02 1.33± 0.02 +6.3c 0.001
(1.13± 0.02) (1.17± 0.02)
a SE: standard error.
b % of variation between 1996 and 2007.
rc Trend for the geometric mean.
Our work has several limitations. The surveys were car-
ried out in three highly contrasted regions, which may not be
representative of the whole of France. Even though the dis-
tributions by age and sex of the three regions were similar,
socioeconomic disparities exist between different French
a
p
a
t
Figure 1. Trends in the prevalence of dyslipidaemias between 1996—1egions and risk factors may differ between our surveys
nd the French population at large. Furthermore, only one
lasma lipid measurement was performed in each survey
nd this may not represent an entirely reliable picture of
he patients’ basic biological values. This is particularly true
997 and 2006—2007 in French adults aged 35—64 years.
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Rigure 2. Trends in the prevalence of dyslipidaemias between 19
ith lipid-lowering drugs.
or triglycerides and HDL-cholesterol levels, where a stable
ifestyle is required to obtain representative parameters.
owever, all biological examinations were centralized in the
ame laboratory for each survey and, as far as we know, no
imilar study has ever been carried out in France. Lastly,
s in all population studies, our work may present selection
ias. The most seriously affected patients, such as the less
ducated and the most underprivileged, may not have par-
icipated. Therefore, our results might offer an optimistic
valuation of lipid management in France. Further studies
ill be needed to ensure that these favourable trends in
ipid levels remain constant throughout time in France.
onclusions
ur study shows a favourable trend in LDL-cholesterol lev-
ls in France at a population level. This improvement is
bserved in the whole population but is more signiﬁcant
n subjects treated with lipid-lowering drugs. A widespread
romotion of preventive messages and treatment with lipid-
owering drugs in agreement with current recommendations
hould be intensiﬁed to reduce cardiovascular morbidity and
ortality.
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